SP Funds S&P 500 Sharia Industry Exclusions ETF vs State Street SPDR S&P Biotech ETF — how do they compare? SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $57.07, while State Street SPDR S&P Biotech ETF trades at $154.4. Which is the better fit depends on your goals.
| SPUS | XBI | |
|---|---|---|
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $59.51 | $164.28 |
52-Week Low | $45.32 | $85.16 |
Signals from Pluang's Aura AI — not financial advice
SPUS trades at $56.32, down 0.23% on the day, with a neutral technical signal overall. The stock shows bullish moving average alignment but oscillators indicate indecision. Recent dividends of $0.03 per share were distributed in April, May, and June 2026, reflecting a stable income component. Key support lies at $56, with resistance near $57.
Outlook remains balanced; dividend consistency supports income investors, but limited fundamental data and neutral technicals suggest cautious optimism. Risks include market volatility and reliance on broader dividend strategy performance. Upside depends on sustained dividend growth and favorable market conditions for income-focused equities.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Trailing returns across standard periods
Latest headlines on both assets
SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.
Read more on SPUS →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →